RNAi of FACE1 protease results in growth inhibition of human cells expressing lamin A: implications for Hutchinson-Gilford progeria syndrome. by Gruber, J. et al.
Introduction
Mammals have three genes for nuclear lamins, the structural
proteins of the nuclear lamina that underlies the inner nuclear
membrane. The lamina associates with chromatin and has been
implicated in the regulation of gene expression and in DNA
synthesis (for a review, see Goldman et al., 2002). Lamin A
and the two B lamins, B1 and B2, differ in expression during
development and display different behaviours during
disassembly of the nuclear envelope prior to cell division.
Lamin A is expressed late in development and in some tissues
even only postnatally (Broers et al., 1997; Röber et al., 1989).
During mitosis, lamin A becomes soluble (Gerace and Blobel,
1980), whereas the B lamins remain bound to membrane
vesicles (Goldman et al., 2002; Moir et al., 2000). All three
lamins end with a CaaX motif that is subject to a series of post-
translational modifications. After farnesylation of the cysteine,
the three terminal residues are removed by a CaaX protease
and the farnesylated cysteine becomes 0-methylated. Lamin A
is subject to an additional and unique maturation step. The
prelamin A is converted to mature lamin A by a proteolytic
conversion. Protein chemical studies indicate cleavage between
Tyr646 and Leu647 (Hennekes and Nigg, 1994; Sinensky et
al., 1994; Weber et al., 1989). The reason for this maturation
is not known, but it explains the solubilization of lamin A in
mitosis. Lamin C is essentially a shortened lamin A form,
which arises by alternative splicing. It has only six unique
residues and ends at position 547. Mice lacking the lamin A
gene develop normally, but their postnatal growth is severely
retarded and they die of muscular dystrophy (Sullivan et al.,
1999). Various reports show that the lamin A gene is connected
to at least eight human diseases (reviewed by Burke and
Stewart, 2002; Mounkes et al., 2003). Among these
laminopathies is also the Hutchinson-Gilford progeria
syndrome (HGPS).
HGPS is a rare genetic human disorder characterised by
features reminiscent of marked premature aging. In a pioneering
analysis Eriksson et al. (Eriksson et al., 2003) found a lamin A
mutation in 20 out of 23 patients with classical HGPS. Of these,
18 harboured an identical de novo, not inherited, single base
substitution G608G (GGC→GGT) within exon 11. This
mutation activates a cryptic splice site within exon 11, resulting
in a mutant protein lacking 50 internal amino acid residues
(609-658) before the C-terminal end (658-664) with its CaaX
motif. In addition, one patient showed a different substitution
within the same codon, and one patient revealed a missense
mutation in exon 2 (E145K). A simultaneously published, but
less extensive study, reported the same mutation G608G in a
patient suffering from mandibuloacral dysplasia with HGPS
features (De Sandre-Giovannoli et al., 2003). Although
occasional missense mutations in lamin A are found (Cao and
Hegele, 2003; Chen et al., 2003; Eriksson et al., 2003; Novelli
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FACE 1 is the endoprotease responsible for cleavage of
prelamin A to lamin A. Transfection of HeLa cells with
siRNA for human FACE 1 results in a strong phenotype.
Protein and mRNA levels for FACE 1 are knocked down
and cell division stops abruptly. Two populations of cells
are detected. The first form aberrant mitotic spindles,
arrest in mitosis and later enter apoptosis. The second show
dramatic changes in nuclear morphology with extensive
formation of lobulated nuclei and micronuclei. Using
antibodies that specifically recognise prelamin A, but not
lamin A, we show that prelamin A accumulates at the
nuclear lamina in FACE1 silenced cells, whereas in control
cells prelamin A is found in many small nuclear dots,
but not at the nuclear lamina. In double knockdown
experiments with FACE 1 and lamin A siRNAs, the results
depend on which protein is knocked down first. FACE1
knockdown 24 hours prior to lamin A knockdown gives
results similar to the single FACE1 knockdown. By
contrast, lamin A knockdown 24 hours prior to FACE1
knockdown results in none of the changes described above.
Silencing of FACE1 in HL60, a cell line that lacks lamin A,
also has no effect. The combined results suggest that
prelamin A is a poison in cells subjected to FACE 1
knockdown. Finally, we draw attention to similarities in
phenotype between FACE1-silenced HeLa cells and
fibroblasts from patients with Hutchinson-Gilford progeria
syndrome containing prelamin A mutations that prevent
cleavage by the FACE1 endoprotease.
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et al., 2002), the major change in HGPS is the deletion of 50
amino acids resulting from a cryptic splice site, which has been
analysed in detail (Eriksson et al., 2003). As this deletion
removes the cleavage site for the conversion of prelamin A to
lamin A, the mutated prelamin A may stay permanently in the
farnesylated form.
Defective prelamin A processing has been clearly
demonstrated in mouse knockouts of the ZMPSTE24
metalloproteinase (Bergo et al., 2002; Pendas et al., 2002).
ZMPSTE24 is an orthologue of the yeast enzyme STE24,
which is involved in the processing of mating pheromone a-
factor, a short peptide ending in a farnesylated, O-methylated
cysteine (Tam et al., 1998). Homozygote knockouts of the
murine gene have a phenotype resembling that of HGPS
patients including growth retardation and premature death from
cardiac dysfunction and alopecia. Cells from such mice lack
mature lamin A and show instead prelamin A (Bergo et al.,
2002; Pendas et al., 2002). Thus murine ZMPSTE24, and its
human orthologue FACE1, may indeed be the proteases
involved in lamin A processing. In line with this view, the
human enzyme expressed in yeast mutants complements a-
factor synthesis (Agarwal et al., 2003; Tam et al., 1998). A
study of four patients with mandibuloacral dysplasia associated
with progeria identified one patient with defects in ZMPSTE24
in the absence of lamin A mutations (Agarwal et al., 2003).
Interestingly recently seven out of nine patients with restrictive
dermopathy showed a premature termination codon in one
gene copy of FACE-1 (Navarro et al., 2004).
Here we report on the functional characterization of the
human endoprotease FACE1 by siRNA mediated gene
silencing. Silencing FACE1 in HeLa cells leads to accumulation
of prelamin A at the nuclear lamina and to a halt in cell division.
One population of FACE1-silenced cells arrest in aberrant
mitosis and later enter apoptosis. The second population show
abnormalities in nuclear morphology including micronuclei
formation. By contrast, when FACE1 was silenced in HeLa cells
lacking lamin A, mitotic arrest does not occur and the cells
appear normal. The similarities seen between the results
described here for FACE1-silenced HeLa cells and results of
others on fibroblasts from Hutchinson-Gilford patients, where
certain mutations in the lamin A molecule prevent cleavage by
the FACE1 enzyme, are discussed.
Materials and Methods
Silencing of FACE1 by siRNA
RNA interference mediated by duplexes of 21-nucleotide RNAs was
performed in human HeLa cells (Elbashir et al., 2001; Harborth et al.,
2001). The siRNA sequence used to target FACE1 was from position
271 to 291 relative to the first nucleotide of the start codon (GenBank
accession number NM_005857). The siRNA targeting lamin A was
from position 608 to 627 (NM_005572). For the mitotic protein Eg5
the siRNA has been described (Harborth et al., 2001). A siRNA
sequence targeting firefly (Photinus pyralis) luciferase (accession
number X 65324) from positions 153 to 175 was used as control
(pGL2 siRNA). The 21-nucleotide RNAs were chemically
synthesised by Dharmacon (Lafayette, CO) and delivered in salt free
and deprotected form.
Cell culture and transfection of siRNA
The human HeLa SS6 and MCF7 cell lines were grown in DMEM
containing 10% foetal calf serum, penicillin and streptomycin at 37°C
with 5% CO2. The human promyelocytic HL60 cell line was grown
in RPMI1640 medium with 10 mM HEPES pH 7.0, 20% foetal calf
serum and penicillin and streptomycin. Transfection with siRNA and
Oligofectamine (Invitrogen, Karlsruhe, FRG; lot number 1122079)
was as described (Elbashir et al., 2002). Cell growth was determined
using an automated microscopy system (CellScreen, Innovartis,
Bielefeld, FRG) by live cell imaging and by measuring the surface of
the wells covered by the cells. HL60 cells were transfected using
electroporation (Nucleofector Technology, Buffer V, Amaxa,
Cologne, FRG).
Antibodies and indirect immunofluorescence microscopy
Primary antibodies were a goat prelamin A antibody (sc06214, batch
number F0303, Santa Cruz Biotechnology, Santa Cruz, CA) that
recognises an epitope in the 20 residues at the C-terminal end and the
monoclonal α-tubulin antibody DM1A (Sigma-Aldrich, Taufkirchen).
In addition we raised a rabbit antiserum against prelamin A using the
synthetic peptide LLGNSSPRTQSPQNC (prelamin A residues 647-
661) linked to ovalbumin. Prelamin A antibodies were purified on the
immobilised peptide. We also used a rabbit antibody raised against
the synthetic peptide CEDSGMEPRNEEEGNSEEI (residues 296-
313) of FACE1 after affinity purification. A second rabbit FACE1
antibody was raised with the peptide corresponding to residues 58-73.
Fluorescently labelled secondary antibodies were from Dianova
(Hamburg, FRG).
Cells grown on glass coverslips were washed with PBS and then
fixed either with –20°C methanol for 10 minutes (for the prelamin A
goat antibody and tubulin antibody) or with 4% paraformaldehyde in
phosphate buffered saline (PBS) at room temperature for 20 minutes
followed by permeabilization with 0.2% Triton X-100 in PBS for 2
minutes at room temperature (for the prelamin A rabbit antibody and
the FACE1 antibody). Fixed cells were washed briefly with PBS.
Primary antibodies were then added and incubated for 1 hour at 37°C
in a humid chamber. Coverslips were washed three times with PBS
and incubated with the labelled secondary antibodies for 1 hour at
37°C. Cells were again washed three times in PBS and stained with
1 µM Hoechst 33342 (Sigma) to visualise the DNA and then were
mounted on glass slides in Mowiol (Hoechst, Frankfurt, FRG).
To stain the endoplasmic reticulum (Terasaki et al., 1984) 1.5 µg/ml
dihexyl oxacarbocyanine iodide in standard culture medium (DMEM)
was added to living HeLa SS6 cells. Cells were incubated at 37°C
with 5% CO2 for 20 minutes. Cells were then fixed with
paraformaldehyde and methanol for FACE1 immunofluorescence.
Western blotting
SDS gel electrophoresis was performed according to standard
protocols. Proteins were transferred to nitrocellulose using the semi-
dry transfer procedure (Kyhse-Andersen, 1984). Membranes were
blocked in TBST (20 mM Tris-HCl, 150 mM NaCl, 0.2% Tween 20,
pH 7.4) containing 5% skimmed milk. The goat and rabbit prelamin
A or rabbit FACE1 antibodies were diluted in the same buffer with
2.5% skim milk and applied for 1 hour at room temperature.
Membranes were washed twice with TBST and once with TBST
containing 0.5% Triton X-100. Affinity-purified horseradish
peroxidase-conjugated rabbit anti-goat or swine anti-rabbit
immunoglobulins were from Dako (Copenhagen, Denmark). They
were diluted 1:10,000 in the blocking buffer with 2.5% skimmed milk
and applied for 2 hours at room temperature. The bands were detected
using ECL (Amersham Biosciences, Piscataway, NJ).
Branched DNA assay
The branched DNA assay (QuantiGene Discovery System,
Genospectra, Fremont, CA) was used for quantification of mRNA











691RNAi of human FACE1 protease
levels in cellular extracts as previously applied to quantify insulin
receptor mRNA (Wang et al., 1997). It is a direct method for
evaluation of mRNA levels, which requires neither RNA isolation
and purification nor any amplification steps. The assay is based on
specific cohybridization of the target mRNA and oligonucleotides
predesigned by Genospectra. A probe set consists of three types
of deoxyoligonucleotides: the capture extenders (CEs) are
complementary to the target mRNA and to nucleotides which are
immobilised in the capture plate, label extenders (LEs) also bind the
target mRNA and the bDNA amplifier for subsequent enzymatic
development and the blocking oligonucleotides (BLs). CEs, LEs and
BLs are designed in a way to hybridise to a 300-500 nucleotide region
along the target mRNA forming a DNA/RNA duplex.
The bDNA assay was performed according to the manufacturer’s
protocol. HeLa SS6 cells were grown in 96-well plates and transfected
as described (Harborth et al., 2001), except that reagents were scaled
down to one sixth of those used for 24 well plates. Cells were
disrupted by application of lysis buffer containing CEs, LEs and BLs.
50 µl lysis buffer and 100 µl medium were applied and cells were
incubated for 1 hour at 37°C. Cells lysates where transferred to the
capture plates, plates were sealed and incubated at 52°C overnight.
Capture plates were washed and incubated with an labelling/amplifier
solution for 1 hour at 37°C. Subsequently plates were developed for
30 minutes at 52°C with the substrate solution. Emitted luminescence
was measured with a luminometer (VICTOR Light, Perkin Elmer,
Wellesley, MA). Target mRNA specific probes for lamin A, FACE1
and β-actin were used. In the data shown here cell extracts were
harvested 24-96 hours post transfection and developed with the
appropriate probes. Data represent levels of FACE1 mRNA and lamin
A mRNA standardised with β-actin mRNA to control for cell numbers
and then normalised using values obtained with control cultures
transfected with GL2 siRNA as 100%.
Apoptosis detection
To detect apoptotic cells a TUNEL test (In situ cell death detection
kit, Roche, Mannheim, FRG) was used. Cells were fixed in –20°C
methanol for 6 minutes and treated with PBS containing 0.1% Triton
X-100 and 0.1% sodium citrate, pH 7.2 on ice for 2 minutes. The free
3′ ends of fragmented DNA were enzymatically labelled with FITC
tagged deoxynucleotide triphosphates using deoxynucleotidyl
transferase (TdT). Labelled DNA fragments were monitored by
fluorescence microscopy.
Results
The endoprotease FACE1 is required for the processing
of prelamin A in HeLa cells
Antibodies that specifically detect prelamin A, but not the
processed lamin A, must recognise the C-terminal sequence of
residues 647-664 (see Introduction). We have used two such
antibodies: a commercial goat anti prelamin A antibody
detecting an epitope in the 20 residues at the C terminal end
and a rabbit antibody which we raised with a synthetic peptide
corresponding to residues 647-661 and purified by antigen
affinity chromatography. Both antibodies gave the same
results.
In normal HeLa cells, as well as in cells transfected with
GL2 siRNA (Fig. 1A, row 1), a low level of prelamin A is
detected in multiple small dots in the nucleoplasm and no
staining of the nuclear lamina is observed. By contrast, in cells
that have been treated with FACE1 siRNA and then stained at
different times after transfection (Fig. 1A, row 2) the prelamin
A accumulated with time at the nuclear lamina. Similar results
were also obtained with the FACE1 silenced human MCF7 cell
line (data not shown). However, silencing with LMNA siRNA
results in a reduction in intensity of the nuclear dots (Fig. 1A,
row 3).
A strong accumulation of prelamin A was also detected in
western blots of extracts from FACE1-silenced HeLa cells
(Fig. 1B). A specific signal with the appropriate molecular
weight for prelamin A was detected only in extracts from the
silenced cells, but not in extracts from cells that were
transfected either with the control GL2 siRNA targeting firefly
Fig. 1. Silencing of human FACE1 results in accumulation of
prelamin A. (A) Human HeLa SS6 cells were immunostained with
the antibody SC06214 recognising an epitope in the C-terminal
region of unprocessed lamin A. This antibody detects prelamin A,
but not lamin A. Transfection with an unspecific GL2 siRNA did not
affect the normal localisation of prelamin A in subnuclear foci (row
1). Transfection with FACE1 siRNA results in progressive
accumulation of unprocessed prelamin A in the nuclear lamina (row
2). Transfection of cells with lamin A siRNA targeting lamin A/C
mRNA resulted in loss of prelamin A (row 3). Hoechst stain of the
same cells (row 4). (B) Accumulation of prelamin A was confirmed
by western blots of FACE1-silenced cells (siFACE1) and control
populations (siGL2). Prelamin A accumulated in FACE1-silenced
cells 48 hours after transfection, but was not detectable in extracts
from cells transfected with the GL2 siRNA. (C) Silencing of FACE1
and lamin A in single siRNA experiments was confirmed by
luminometric measurement of absolute mRNA levels via the
branched DNA assay. Note that after 24 hours the mRNA is very
much reduced for both targets and that these low levels are












(Photinus pyralis) luciferase (Fig. 1B) or with lamin A siRNA
(data not shown). The level of FACE1 endoprotease was
strongly reduced after silencing with FACE1 siRNAs (Fig. 1B).
Successful silencing of FACE1 by transfection of FACE1
siRNA was confirmed by the novel branched DNA (bDNA)
assay (Fig. 1C). This assay allowed direct luminometric
measurement of mRNA levels from cell extracts by specific
immobilization of target mRNAs and labelling with DNA
probes. Samples were derived from FACE1, LMNA or GL2
siRNA-transfected HeLa cells. mRNA levels from GL2 cells
were used for normalization of values obtained from silenced
cell populations. The bDNA assay showed a reduction of about
80% in the FACE1 and LMNA mRNA levels 24 hours after
transfection. Thus, this new method appears to be an
appropriate technique for quantification of mRNA knockdown
in RNAi experiments.
The combined results suggest that after loss of the
endoprotease, FACE1 cells were unable to process farnesylated
prelamin A by cleavage of the C-terminal 18 amino acids, and
that in consequence prelamin A may be incorporated in place
of the normal, processed lamin A into the nuclear lamina.
FACE1 knockdown causes changes in nuclear
morphology as well as aberrant mitosis
Two populations could be distinguished in cells treated with
FACE1 siRNA. The first population (Fig. 2) showed changes
in nuclear morphology with many cells displaying micronuclei.
The second population (Fig. 3) was formed by cells that
arrested in aberrant mitosis and later underwent apoptosis.
Accumulation of prelamin A in HeLa cells led to dramatic
changes in the nuclear architecture with increasing time after
transfection with FACE1 siRNA (Fig. 2). These changes
included folds in the nuclear envelope, herniations and crevices
extending into the nuclear periphery as well as lobulation and
increasing fragmentation of nuclei and formation of
micronuclei. All effects could be detected early after siRNA
transfection (24 hours), but the percentage of cells displaying
more severe effects increased with time post transfection (see
Fig. 2B). Micronuclei were observed in 30% of the cells 120
hours post transfection (Fig. 2C).
A very striking change observed after knockdown of the
FACE1 endoprotease was the accumulation of cells in aberrant
mitosis (Fig. 3). Cells were arrested in early metaphase and
displayed disturbed spindle architecture and abnormal
chromosome congression (Fig. 3A, row 1). Analysis of
FACE1-silenced cells by the TUNEL assay showed that the
cells in this population underwent apoptosis following the
aberrant mitotic arrest (Fig. 3B, row 1). Quantification of cells
in mitotic arrest and apoptosis are shown in Fig. 3C and D.
After 24 hours, 25% of the cells were arrested in mitosis and
after 48 hours this value increased to a maximum of 35% (Fig.
3C). At later times, the percentage of cells arrested in aberrant
mitosis decreased. The percentage of cells that were apoptotic
reached a maximum 72 hours post transfection with FACE1
siRNA (Fig. 3D).
Measurements of cell growth were made with the CellScreen
System for the FACE1 siRNA transfected cells, as well as for
GL2 and LMNA transfected cells (Fig. 3E). Cells transfected
with FACE1 siRNA stopped growing abruptly. LMNA silenced
cells showed a small reduction in growth rate (see also Elbashir
et al., 2002) when compared to the GL2 control, but the change
in growth rate was minor in comparison to that seen with the
FACE1-silenced cells.
The phenotypic changes after FACE1 silencing are due
to the increase in prelamin A
Double RNAi experiments were performed to see whether the
phenotypic changes were due to the accumulation of prelamin
Journal of Cell Science 118 (4)
Fig. 2. Silencing of FACE1 causes abnormalities in
nuclear morphology. (A) Control HeLa cells (a)
show a normal nuclear morphology whereas FACE1-
silenced HeLa cells display a range of abnormal
nuclear morphologies (b-h) when stained with
Hoechst dye. The abnormalities included minor
effects such as herniations in the nuclear periphery
(b) and folds (c-f), or more severe effects such as
lobules (f) and fragments (g) as well as formation of
micronuclei (h). The number of cells with severe
abnormalities increased significantly at later times
after transfection. (B) Comparative statistics. Cells
were divided into four classes. ‘Normal’ nuclei have
a morphology as in a; ‘folds and herniations’ as in c-
f, fragmentation as in g; and micronuclei as in h. The
percentage of normal nuclei decreased from 60% at
24 hours to 20% at 72 hours. Folds and herniations
reached a maximum (>40%) 48 hours after
transfection and then decreased slowly. The number
of cells with micronuclei increased throughout the
observation time and reached a maximum (>30%)
120 hours post transfection. (C) Cells treated with
FACE1 siRNAs in-phase superimposed with
prelamin A stain (red) and Hoechst DANN stain
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A. Mitotic arrest and the changes in nuclear morphology were
not observed when lamin A was silenced 24 hours before the
FACE1 knockdown (Fig. 4A, top). Thus, when cells were
stained with tubulin antibodies, normal mitotic spindles were
seen and mitotic cells with abnormal multipolar spindles were
not found. By contrast, if FACE1 was silenced 24 hours before
lamin A was silenced, results were similar to those reported
above for FACE1 silencing alone in that accumulation of cells
with aberrant mitotic arrest was observed 48 hours after the
first transfection (Fig. 4A, bottom). These data strongly suggest
that the accumulation of prelamin A is the cause of the effects
seen in HeLa cells.
The bDNA assay was used to confirm that both FACE1 and
lamin A were knocked down when a double RNAi experiment
was performed. In the double knockdown experiment leading
to normal mitosis, i.e. knockdown of lamin A followed 24
hours later by knockdown of FACE1 (LMNA-FACE1), mRNA
levels are reduced to 20% when assayed 24 hours after the
second transfection (*, Fig. 4B). When FACE1 is knocked
down 24 hours prior to LMNA (FACE1-LMNA), again a
reduction in mRNA levels for both proteins is seen with the
FACE1 mRNA more strongly reduced than the LMNA
mRNA.
Other double RNAi experiments were also done using
control GL2 siRNAs followed 24 hours later by transfection
with either FACE1 or with lamin A siRNAs. As can be seen
from Fig. 4B, use of the GL2-FACE1 combination results in
knockdown of FACE1 but not of lamin A mRNA, whereas use
of the GL2-LMNA combination knocks down lamin A but not
FACE1. In other double RNAi experiments (data not shown)
HeLa cells were transfected with GL2 siRNAs followed 24
hours later with siRNAs for the Eg5 motor protein, or with GL2
siRNAs followed by β-actin siRNAs. The phenotype obtained
with the GL2-Eg5 was the same as those seen when cells are
transfected only with Eg5 siRNAs. Likewise the phenotype
obtained with the GL2-β-actin combination was identical to
Fig. 3. Aberrant mitosis and apoptosis are consequences of FACE1 knockdown. (A) RNAi mediated knockdown of FACE1 led to mitotic arrest
of HeLa SS6 cells within 24 hours of transfection. Arrested cells (top) displayed abnormal mitotic spindle architecture and disturbed
chromosome congression. Control cells (bottom) transfected with GL2 siRNA showed normal mitosis. Cells were stained with tubulin antibody
and with Hoechst dye. (B) TUNEL assay on FACE1-silenced (top) and control cells (bottom) 72 hours after siRNA transfection shows that the
mitotically arrested cells have entered apoptosis. (C) Quantification of mitotic arrest after FACE1 silencing. The fraction of cells showing
mitotic arrest increased with time after transfection, reaching a maximum of 35% of the total cell population at 48 hours. Cells transfected with
either GL2 or with lamin A siRNA did not arrest in mitosis. (D) Quantification of apoptosis after FACE1 silencing. The percentage of apoptotic
cells reached a maximum of 25% 72 hours after transfection and then decreased. Apoptosis was observed only in FACE1-silenced cells, but not
in control (GL2 siRNA) or in lamin A siRNA-transfected cells. (E) Cell growth measured with the CellScreen apparatus was reduced












that seen with β-actin in a single RNAi transfection experiment
(Harborth et al., 2001). The double RNA experiments in Fig.
4, as well as the double RNAi experiments with Eg5 and β-
actin suggest that the consecutive use of two different RNAi
transfections will become a very useful tool in RNAi
technology.
Additional confirmation that the phenotypic changes after
FACE1 silencing are due to the increase in prelamin A, comes
from the HL60 cell line. This human promyelocytic cell line
does not express the lamin A gene. When HL60 cells were
transfected by electroporation with FACE1 siRNA, no growth
retardation, mitotic arrest or effects on nuclear architecture
were observed (data not shown).
Location of FACE1 in HeLa cells
The immunofluorescence results in Fig. 5 show that in HeLa
cells FACE1 is located in spots at the nuclear membrane and
in the endoplasmic reticulum. Staining of the endoplasmic
reticulum was confirmed by first staining live cells with 3,3’
dihexyloxacarbocyanine iodide and then with FACE1
antibodies. In cells transfected with FACE1, siRNA staining at
the nuclear membrane and in the endoplasmic reticulum is very
strongly reduced 48 hours after transfection.
Journal of Cell Science 118 (4)
Fig. 4. Double RNAi suggests prelamin A is responsible for
phenotypic changes after FACE1 silencing. (A) Silencing of lamin A
prior to FACE1 prevented phenotypic changes. Human HeLa SS6
cells were transfected with the siRNA specific for the first target and
after 24 hours with the second siRNA. Cells were stained for tubulin
and for DNA 24 hours after the second transfection.
(a,b) Knockdown of lamin A before FACE1 did not cause abnormal
mitosis, apoptosis or changes in the nuclear morphology.
(c,d) Silencing of FACE1 prior to silencing of lamin A led to
aberrant mitotic arrest. (B) Successful transfection in the double
knockdown experiments was confirmed by the branched DNA assay.
Data represent the relative mRNA levels 24 hours after the second
transfection for the LMNA-FACE1 combination () and for the
FACE1-LMNA combination. Double siGL2 transfection was used
for normalisation (GL2). That the second transfection was effective
was further confirmed by transfecting either FACE1 or lamin A
siRNA 24 hours after siGL2 delivery (GL2-FACE1 and GL2-
LMNA). Bar, 10 µm.
Fig. 5. Immunofluorescence detection of FACE1 in the endoplasmic
reticulum and the nuclear periphery. (A) HeLa cells were stained
with dihexyloxacarbocyanine iodide to label the endoplasmic
reticulum and then with the rabbit FACE1 antibody against residues
296-313. FACE1 is seen in the endoplasmic reticulum identified by
DiOC6 staining and is also seen in spots at the nuclear periphery.
(B) Immunofluorescence with the FACE1-specific antibody 48 hours
after transfection of FACE1 or GL2 siRNA demonstrates silencing of
FACE1 in cells transfected with FACE1 siRNA, but not in cells
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Discussion
Here we have successfully silenced the human endoprotease
FACE1 by RNA interference using the siRNA technique
(Elbashir et al., 2001; Harborth et al., 2001). To document
silencing after transfection of target specific siRNA a novel
technique was introduced. The new bDNA assay (Wang et al.,
1997) allowed quantitative determination of the absolute
mRNA levels without the pitfalls of RNA extraction,
purification and amplification steps as required in real-time
PCR approaches. Thus FACE1 and lamin A knockdown could
be confirmed on the quantitative mRNA level as well as on the
protein level using indirect immunofluorescence microscopy
and western blotting.
In control HeLa cells, only small amounts of prelamin A are
present. Prelamin A is located to spots within the nuclei, but
not to the nuclear lamina (Fig. 1A). Similar results have been
reported for control fibroblasts (Goldman et al., 2004). Western
blotting of control cells with prelamin A specific antibodies
shows no band at the prelamin A position in control cells (Fig.
1B). By contrast, in HeLa and MCF7 cells RNAi of FACE1
results in accumulation of relatively large amounts of
unprocessed prelamin A at the nuclear membrane both by
immunofluorescence (Fig. 1A) and by immunoblotting (Fig.
1B) within 24-48 hours after transfection. These findings
support results on the ablation of the murine gene. Ablation of
ZMPSTE24 showed an accumulation of prelamin A owing to
defective processing of prelamin A (Bergo et al., 2002; Pendas
et al., 2002). They further establish that prelamin A is a
substrate of ZMPSTE24 and that its accumulation results in
HGPS-related defects, but they do not show whether FACE1
has other substrates in addition to prelamin A (Bergo et al.,
2002; Pendas et al., 2002). Our results with the HeLa cell
system are therefore of particular interest. They show that the
loss of FACE1 leads only to the strong phenotypes when the
cells express the lamin A gene. When HeLa cells are subjected
to an RNAi knockdown of lamin A (Elbashir et al., 2001;
Elbashir et al., 2002; Harborth et al., 2001), such cell
populations behave normally when FACE1 is subsequently
downregulated by RNAi (Fig. 5A). We have confirmed by the
branched DNA assay that such cells indeed have a strongly
reduced level of FACE1 mRNA (Fig. 1C). Thus it seems that
at least in normal HeLa cells, prelamin A is an important
substrate of FACE1 and that other substrates, if they exist, are
not of immediate importance for cellular growth. The finding
that HL60, a cell line that does not express the lamin A gene,
shows no effects on FACE1 silencing supports this conclusion.
A variety of interesting phenotypic changes have been
observed in the siRNA-transfected HeLa cells in addition to
the accumulation of unprocessed lamin A at the nuclear
membrane (Figs 1-5). Two cell populations are detected after
silencing with FACE1 siRNA. The first population shows
changes in nuclear morphology. Nuclei lose their shape,
develop folds and lobulation and show progressive
fragmentation (Fig. 2). Presumably these changes are due to
differences between how prelamin A and lamin A incorporate
into the nuclear lamina. The second population is characterised
by multipolar spindles and arrest in mitosis (Fig. 3A). The
percentage of cells in mitotic arrest reaches a maximum of 31%
at 48 hours (Fig. 3C). These cells become apoptotic with the
percentage of cells in apoptosis reaching 25% at 72 hours
(Fig. 3D). The cause of disturbed spindle architecture and
chromosome congression in metaphase is unclear, but
presumably results from changes in lamina stability and
protein/DNA interactions. Farnesylated, 0-methylated
prelamin A could have similar membrane anchoring or
hydrophobic interaction properties as the B type lamins (i.e.
lamin B1 and lamin B2) and therefore, like B lamins, might
remain connected to structures of the nuclear envelope when
cells enter mitosis. By contrast, mature lamin A is
phosphorylated at the beginning of mitosis, depolymerises, and
is soluble in the cytoplasm until it is reassembled on the inner
face of the nuclear envelopes in the daughter cells (for reviews,
see Goldman et al., 2002; Moir et al., 2000).
Fibroblasts from both ZMPSTE24 deficient mice (Pendas et
al., 2002) and from HGPS patients (Eriksson et al., 2003) show
abnormalities in nuclear morphology and in this respect are
therefore similar to the FACE1-silenced HeLa cells studied
here. Fibroblasts from HGPS patients show the same
progression of changes in nuclear morphologies that we
observed upon FACE1 silencing, starting with folds and
herniations, fragmentation of nuclei and ending with
micronucleated cells. In addition, a high percentage of cells are
apoptotic at late passages of HGPS-derived fibroblasts (Bridger
and Kill, 2004). The most common HGPS mutation was
originally identified as an ablation of the FACE1 cleavage site
in prelamin A (Eriksson et al., 2003). Accumulation of
prelamin A at the nuclear membrane has been noted in cells
from a HGPS patient with this mutation (Goldman et al., 2004),
thus paralleling our results with FACE1 silenced HeLa cells.
The rapid effects on mitosis of FACE1 negative silenced
cells indicate a fast intracellular turnover of the protease, since
already 24 hours after siRNA delivery a high percentage of
cells displayed silencing specific defects and had begun to
accumulate prelamin A (Fig. 1A, Fig. 4). The results from the
CellScreen measurements (Fig. 3E) show that there is a
dramatic arrest in cell growth in the FACE1 siRNA-treated
cells.
Relatively little is known about consequences of mutations
in the FACE1 gene, which maps to chromosome 1p34.
Agarwal and colleagues described a Belgian family with
mutations in FACE1 (Agarwal et al., 2003). A frameshift
mutant introducing an early termination codon provides an
inactive enzyme and a missense mutation in a highly conserved
region (W340R) yields reduced enzymatic activity. Individuals
who were heterozygous for one of these two mutations seem
normal, whereas a patient with both mutations had
mandibuloacral dysplasia with progeroid appearance and
generalised lipodystrophy and died aged 24 years. Recently,
the lamin A and FACE1 genes were sequenced from nine
patients with restrictive dermopathy (RD) (Navarro et al.,
2004). Two had a heterozygous splicing mutation in the lamin
A gene, leading to the complete or partial loss of exon 11 in
the mRNAs that resulted in a truncated prelamin A. In the other
seven patients, a unique heterozygous one base pair insertion
in exon 9 led to the creation of a premature termination codon
in FACE1. In cells grown in culture from patients with FACE1
mutations, loss of normal lamin A expression was observed
and in the first three cell divisions up to 50% of cells had nuclei
that were abnormal in shape or size. The authors suggest that
the FACE1 mutation identified in their study is a necessary but












in four families the same mutation was present in one of the
parents who was free of disease (Navarro et al., 2004). They
further suggest that a second gene may be mutated in patients
with restrictive dermopathy.
In conclusion, in HeLa cells expressing lamin A, the
knockdown of the endoprotease FACE1 has deleterious effects.
As these do not occur after lamin A expression is suppressed
by RNAi, we propose that the large increase in unprocessed
prelamin A may be the direct cause for the lethal phenotype.
Although we do not yet understand the cell biological effects
in detail, the presence of the permanently farnesylated/0-
methylated C-terminal cysteine could have severe effects on
lamin A assembly, organisation and function that appear
related to those postulated for HGPS patients (Goldman et al.,
2004). The HeLa system established here should be very useful
for further detailed studies.
We thank Jürgen Wehland (GBF Braunschweig) for a generous
supply of antibodies, Martin Zeidler’s group for help with the
luminometer measurements and H.-J. Dehne for expert technical
assistance.
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